Trial intelligence / Profile preview

TABRECTA in MET exon 14-mutated NSCLC (China Phase II)

CTR20210057Phase 2Completed

Sponsor

Novartis

Start

Jan 2021

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1